Ken Westover, M.D., Ph.D.

Physician scientist at UT Southwestern focused on the discovery of new cancer therapies. Tweets are my own.

[Ken Westover, M.D., Ph.D. @kenwestover]

Thank you to everyone in Biochemistry and Radiation Oncology for helping us to make this happen. Special thanks to everyone in the lab for sorting, packing, and bearing with this process. Fingers crossed for tomorrow 🤞

[Ken Westover, M.D., Ph.D. @kenwestover]

The lab is moving to UTSW north campus tomorrow. Looking forward to working more closely with the new Molecular Medicine group there. Wish us luck!

[Ken Westover, M.D., Ph.D. @kenwestover]

@BadiyanMD @IJROBP @UTSW_RadOnc @BadiyanMD - you are too kind. Enjoyed working on this!

[Ken Westover, M.D., Ph.D. @kenwestover]

@rdfoster88 @UTSW_RadOnc @UTSWTechDev MRI compatible. Otherwise it is intended to be similar.

[Ken Westover, M.D., Ph.D. @kenwestover]

Fun to see this article about the recent @UTSWTechDev pitch competition! Anyone need an SBRT frame? I know a guy. 😄 Fantastic event! @utsw_radOnc https://t.co/aNdUYUyToW

[Ken Westover, M.D., Ph.D. @kenwestover]

We're excited about our new paper - measuring kinase activity using high-throughput mass spectrometry. This technique is great for inhibitor work - fast, label-free, and sensitive. Eager to expand the assay panel and collaborate! @UTSWNews, @UTSW_RadOnc https://t.co/9qQSpFXWwG

[Ken Westover, M.D., Ph.D. @kenwestover]

Interested in using structural biology, biochemistry and informatics to design drugs that fight cancer? My lab is looking for qualified post doctoral fellows/scientists to join us @UTSWNews in Dallas. Here is the ad: https://t.co/2rhyoZHCOC #KRAS, #kinases

[Ken Westover, M.D., Ph.D. @kenwestover]

Congrats to Kari Kopra @UniTurku and collaborators (@UZH_en, @FredNatLab) on a new paper. New thermal shift assay for proteins, featuring #KRAS. @UTSWNews, @UTSW_RadOnc, @UZH_en, @FredNatLab. https://t.co/UTO8qzLXue

[Behnam Nabet @behnamnabet]

We are grateful to our incredible team of collaborators for all their help, support, and contributions: Yan Liu and @kenwestover @UTSW_RadOnc, @JSheltzer @YaleMed, Matt Robers @promega, Nathanael Gray and the whole Gray lab team @Stanford_ChEMH @DFCI_ChemBio.

[Ken Westover, M.D., Ph.D. @kenwestover]

I see the CDK11 inhibitor paper is posted. Congratulations @ZhengnianLi, Ryosuke, Yan Liu, @behnamnabet and all others I can't fit here. Was fun working with you. @UTSWNews, @ChemSysBio, @UTSW_RadOnc https://t.co/MLyKdH06Nd

[Ken Westover, M.D., Ph.D. @kenwestover]

Exciting work by Sudershan Gondi on scalable acid catalyzed synthesis of medicinal compounds, published in JOC today - https://t.co/NU0HVcBo7i. Well done! Thank you @utsw biochemistry and @UTSW_RadOnc for encouragement and support. @UTSWNews #medchem #chemtwitter #drugdiscovery

[Ken Westover, M.D., Ph.D. @kenwestover]

Congratulations to George Zhou and collaborators on the #PDL1 P146R mutation paper, out this morning. What does P146R have to do with checkpoint inhibitors? Have a look ... https://t.co/5sgEolWvSN @UTSW_RadOnc @utswcancer

[Ken Westover, M.D., Ph.D. @kenwestover]

Check out the #KRAS signalosome model now published in NSMB. What an enjoyable, miraculous collaboration! Thank you everyone. @DEShawResearch @Ambrogiolab @XiaochenBai @UTSW_RadOnc @utswcancer
https://t.co/ZyxtuGMSTl

[Ken Westover, M.D., Ph.D. @kenwestover]

For anyone interested I'll be speaking at #MAP2021 about @Targeting KRAS: Past, Present, Future, Industry Sponsored Satellite Symposium, October 9th, 1100-1200 CET
ESMO MAP takes place virtually from 7-9 October
https://t.co/MV7F2oBmL7

[Ken Westover, M.D., Ph.D. @kenwestover]

@ChadPecot @utsw Great question. I hadn't thought about it that way, but I suppose if a pan-RAS inhibitor was marginally effective against mKRAS, but hits WT hard it could theoretically lead to progression. Did I catch your meaning?

[Ken Westover, M.D., Ph.D. @kenwestover]

New paper! Wild type #KRAS suppresses mutant KRAS. Does that mean loss of wild type (LOH) leads to cancer progression in people? We found an association. LOH also associates with upregulation of #FASN -> therapeutic opportunities. https://t.co/8pygW2GpLm. Congrats @utsw team!

[Ken Westover, M.D., Ph.D. @kenwestover]

Our collaborative @biorxivpreprint on a #KRAS signalosome model is out. Model is based on simulations done by @DEShawResearch and validated by cell-based assays and EM. Thanks all for the fantastic collaboration. https://t.co/hhnqIje475.

[Ken Westover, M.D., Ph.D. @kenwestover]

I'm looking for a technician to join my lab at #UTSW https://t.co/JCfZKLJTsg to work on a drug discovery project. Would be a good fit for a recent college graduate living in DFW with research experience. Here is the job posting: https://t.co/vRm2ov0dtZ

[Ken Westover, M.D., Ph.D. @kenwestover]

Our paper on this x-ray structure of SRC with a covalent inhibitor is now posted. Congratulations Deepak and team! Thanks to the Gray lab for collaboration! #UTSW #CovalentModifiers https://t.co/l2niD8sPnE

[Ken Westover, M.D., Ph.D. @kenwestover]

Our study on hippocampus-sparing whole brain with integrated boost (HSIB-WBRT) is now posted online. Regimen was 16Gy to hippo, 20Gy to at-risk brain and 40Gy to mets. Interesting to compare intracranial control to CC001 (no boost). #UTSW #radonc https://t.co/ALGs8mFRXD